Cellectis S.a. (CLLS) Live Share Price, Invest From India

Cellectis S.a. Stock Performance

as on January 28, 2026 at 9:40 pm IST

Day's Low
Day's High
$4.00
Day's Price Range
$4.12
$4.04
0.99%
Downside
1.98%
Upside
52 Week's Low
52 Week's High
$1.10
52-Week Price Range
$5.48
$4.04
72.77%
Downside
35.63%
Upside

Cellectis S.a. share price movements today

Previous Close: $4.23
Open: $4.12
Volume: 20.5K
Day's Low - High: $4.00 - $4.12
52 Week Low - High: $1.10 - $5.48

Cellectis S.a. Historical Returns

1 Month Return: -10.95 %
3 Month Return: + 18.16 %
1 Year Return: + 174.68 %
3 Year Return: + 36.45 %
5 Year Return: -85.03 %

Cellectis S.a. Stock Fundamentals & Key Indicators

Check Cellectis S.a. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$416.7M

EPS (TTM)

-0.47

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-13.9M

Revenue (TTM)

82.6M

Profit Margin

-42.83%

Return On Equity TTM

-30.75%

Cellectis S.a. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cellectis S.a. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Cellectis S.a.	BUY	$416.7M	-85.03%	NA	-42.83%
Alnylam Pharmaceuticals, Inc.	BUY	$47.7B	129.26%	1246.03	1.36%
Vertex Pharmaceuticals Incorporated	BUY	$122.3B	106.13%	33.56	31.35%
Beone Medicines Ltd	NA	$37.4B	NA	662.33	1.38%
Regeneron Pharmaceuticals, Inc.	BUY	$80.8B	52.34%	18.28	32.13%

Stock Returns calculator for Cellectis S.a. Stock including INR - Dollar returns

The Cellectis S.a. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Cellectis S.a. investment value today

Current value as on today

₹2,68,312

Returns

₹1,68,312

(+168.31%)

Returns from Cellectis S.a. Stock

₹1,62,338 (+162.34%)

Dollar Returns*

₹5,974 (+5.97%)

Analyst Recommendation on Cellectis S.a. Stock

Based on 14 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 14 analysts, 85.71% of analysts recommend a 'BUY' rating for Cellectis S.a.. Average target price of $7.2

Cellectis S.a. Share Price Target

Get share price movements and forecasts by analysts on Cellectis S.a..

What analysts predicted

43.89%UPSIDE

Target Price

$7.2

Current Price

$4.04

Analyzed by

14 Analysts

Target

$7.20

Cellectis S.a. target price $7.2, a slight upside of 43.89% compared to current price of $4.04. According to 14 analysts rating.

Cellectis S.a. Stock’s Investor Sentiment and Interest

Search interest for Cellectis S.a. Stock has decreased by -21% in the last 30 days, reflecting a downward trend in search activity.

Time period: December 29, 2025 to January 28, 2026

Change:-21% versus previous 30 day period

Cellectis S.a. Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Total Revenue	0	0	0	4	8	16	12	10	16	35
Gross Profit	0	0	0	2	6	13	10	8	14	32
Operating Income	-23	-20	-29	-20	-17	-10	-10	-14	-9	8
EBITDA	-23	-11	-56	11	-18	-16	14	-11	-16	7
Interest Expense	1	1	17	1	1	2	1	1	2	2
Depreciation	4	4	5	4	4	4	5	4	5	5
Income Before Tax	-7	-17	-63	5	-25	-23	6	-18	-23	0
Income Tax Expense	0	0	0	0	0	0	0	0	0	-
Net Income	-10	-17	-42	5	-25	-23	5	-18	-23	0
Net Profit Margin	-5982.02%	-11278.71%	-15145.58%	124.62%	-313.48%	-142.32%	46.57%	-170.14%	-141.91%	1.67%

Cellectis S.a. Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	55	42	25	12	15	73	73	19	0	41
Gross Profit	52	40	22	9	3	37	37	17	-6	32
Operating Income	-30	-63	-92	-105	-123	-85	-85	-89	-97	-59
EBITDA	-26	-65	-108	-102	-116	-75	-68	-71	-92	-9
Interest Expense	0	0	0	0	2	12	5	3	5	7
Depreciation	-	-	3	2	6	9	16	18	18	19
Income Before Tax	-22	-63	-103	-88	-115	-97	-97	-98	-116	-36
Income Tax Expense	0	-1	-13	16	-24	-24	-11	0	0	-6
Net Income	-22	-63	-99	-78	-90	-72	-86	-98	-101	-36
Net Profit Margin	-40.81%	-150.10%	-394.51%	-618.12%	-597.01%	-98.14%	-116.68%	-514.78%	-13385.30%	-88.57%

Cellectis S.a. Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Net Income	-17	-63	5	-25	-23	5	-18	-23	0
Operating Cash Flow	-17	39	-23	52	-5	0	-17	-10	-1
Investing Cash Flow	0	-13	-2	-106	22	-16	4	-52	-3
Financing Cash Flow	1	41	11	78	-4	2	-4	-4	-4
Change in Cash	-17	69	-13	26	10	-15	-15	-67	-7

Cellectis S.a. Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-63	-103	-88	-115	-53	-96	-98	-116	-36
Operating Cash Flow	-31	-52	-68	-69	-80	-104	-87	-24	22
Investing Cash Flow	-50	1	35	-35	-54	7	-2	-15	-102
Financing Cash Flow	0	41	236	-3	27	47	1	82	89
Change in Cash	-76	1	195	-110	-99	-55	-92	43	6

Global Institutional Holdings in Cellectis S.a.

Funds	Holdings
LPL Financial Corp	0.09%
Millennium Management LLC	0.04%
UBS Group AG	0.03%
JPMorgan Chase & Co	0%
B Group, Inc	3.25%

See all

Cellectis S.a. News & Key Events

Insights on Cellectis S.a.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -23.73M → 589.0K (in $), with an average increase of 4129.7% per quarter
POSITIVE IMPACT
Best in 1 Year
In the last 1 year, CLLS has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Price Rise
In the last 1 year, CLLS stock has moved up by 174.7%
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 10.65M → 35.17M (in $), with an average increase of 44.4% per quarter
POSITIVE IMPACT
Best in 3 Years
In the last 3 years, CLLS has outperformed top 5 stocks with highest market-cap in its industry

About Cellectis S.a.

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Organisation	Cellectis S.a.
Headquarters	8, rue de la Croix Jarry, Paris, France, 75013
Industry	Health Technology
CEO	Dr. Andre Choulika Ph.D.
E-voting on shares	Click here to vote

Key Management of Cellectis S.a.

Name	Title
Dr. David J. Sourdive Ph.D.	Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director
Mr. Arthur Stril	CFO & Chief Business Officer
Ms. Marie-Bleuenn Terrier	General Counsel & Secretary of the Board of Directors
Pascalyne Wilson	Director of Communications
Ms. Kyung Nam-Wortman	Executive VP & Chief Human Resources Officer
Mr. Stephan Reynier M.Sc.	Chief Regulatory & Pharmaceutical Compliance Officer
Dr. Andre Choulika Ph.D.	Co-Founder, CEO & Director
Valerie Cros	Principal Financial Officer & Principal Accounting Officer
Mr. Jean Charles Epinat Ph.D.	Chief Technological Officer
Dr. Philippe Duchateau Ph.D.	Chief Scientific Officer

FAQs

What is Cellectis S.a. share price today?

Cellectis S.a. share price today is $4.04 as on January 28, 2026 at 9:40 pm IST. Cellectis S.a. share today touched a day high of $4.12 and a low of $4.

What is the 52 week high and 52 week low for Cellectis S.a. share?

Cellectis S.a. share touched a 52 week high of $5.48 on October 16, 2025 and a 52 week low of $1.1 on April 7, 2025. Cellectis S.a. stock price today i.e. January 28, 2026 at 9:40 pm IST is trending at $4.04,which is 26.27% down from its 52 week high and 267.27% up from its 52 week low.

What is Cellectis S.a.'s market capitalisation today?

Cellectis S.a. market capitalisation is $0.00T as on January 28, 2026 at 9:40 pm IST.

How to invest in Cellectis S.a. Stock (CLLS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Cellectis S.a. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cellectis S.a. Shares that will get you 0.3713 shares as per Cellectis S.a. share price of $4.04 per share as on January 28, 2026 at 9:40 pm IST.

What is the minimum amount required to buy Cellectis S.a. Stock (CLLS) from India?

Indian investors can start investing in Cellectis S.a. (CLLS) shares with as little as ₹91.762 or $1 (as of January 28, 2026 at 9:40 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹917.62 in Cellectis S.a. stock (as per the Rupee-Dollar exchange rate as on January 28, 2026 at 9:40 pm IST). Based on Cellectis S.a. share’s latest price of $4.04 as on January 28, 2026 at 9:40 pm IST, you will get 2.4752 shares of Cellectis S.a.. Learn more about fractional shares .

What are the returns that Cellectis S.a. has given to Indian investors in the last 5 years?

Cellectis S.a. stock has given -85.03% share price returns and 25.73% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?